Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Catalyst Grant: Avian Influenza OneHealth Research

Université Laval

$150,000.00

Antiviral drug resistance in avian influenza viruses

FY 2024-25

Summary
One of the circulating avian influenza H5N1 viruses, clade 2.3.4.4b, has the unique capability to infect many species of mammals such as cats, racoons, dogs, minks and marine mammals. As of July 3, 2024, 4 US individuals tied to dairy cattle have been infected with this strain but none from Canada so far. Contamination with raw cow's milk is a potential transmission route although pasteurization was shown to inactivate H5N1 viruses. Despite the fact that those recent human cases were not very sick (they mainly had conjunctivitis), there is a risk of dissemination of this highly pathogenic strain to humans considering the detection of mammalian adaptation mutations already present in those viruses. Besides vaccines, antivirals have an important role in the control of influenza viruses. However, the need of early intervention (typically within 48 hours) and the emergence of resistance are well-known limitations of these agents targeting the viral neuraminidase (NA) or polymerase (pol). The recent H5N1 clade has been shown to be susceptible to these classes of antivirals, although prior H5N1 strains resistant to neuraminidase inhibitors have been reported so that active surveillance for drug resistance mutations is a priority. The objective of this proposal is to develop safe and rapid strategies to assess the drug phenotype associated with NA and pol mutations leading to antiviral drug resistance previously reported in other viral subtypes (such as H1N1) or those of unknown significance found in clinical and animal samples. At term, such rapid genotype to phenotype assays should result in improved treatment and will inform on drug stockpiling strategy in case of pandemic.
Program
Catalyst Grant: Avian Influenza OneHealth Research
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
507170
Name
Boivin Guy
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Catalyst Grant: Catalyzing OneHealth Research on Avian Influenza
Projecttitle
Antiviral drug resistance in avian influenza viruses
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Catalyst Grant: Avian Influenza OneHealth Research
Keyworddelim
Antiviral; Avian; Baloxavir; H5n1; Influenza; Neuraminidase Inhibitors; Oseltamivir; Pa Inhibitors; Resistance; Zanamivir
Abstract
One of the circulating avian influenza H5N1 viruses, clade 2.3.4.4b, has the unique capability to infect many species of mammals such as cats, racoons, dogs, minks and marine mammals. As of July 3, 2024, 4 US individuals tied to dairy cattle have been infected with this strain but none from Canada so far. Contamination with raw cow's milk is a potential transmission route although pasteurization was shown to inactivate H5N1 viruses. Despite the fact that those recent human cases were not very sick (they mainly had conjunctivitis), there is a risk of dissemination of this highly pathogenic strain to humans considering the detection of mammalian adaptation mutations already present in those viruses. Besides vaccines, antivirals have an important role in the control of influenza viruses. However, the need of early intervention (typically within 48 hours) and the emergence of resistance are well-known limitations of these agents targeting the viral neuraminidase (NA) or polymerase (pol). The recent H5N1 clade has been shown to be susceptible to these classes of antivirals, although prior H5N1 strains resistant to neuraminidase inhibitors have been reported so that active surveillance for drug resistance mutations is a priority. The objective of this proposal is to develop safe and rapid strategies to assess the drug phenotype associated with NA and pol mutations leading to antiviral drug resistance previously reported in other viral subtypes (such as H1N1) or those of unknown significance found in clinical and animal samples. At term, such rapid genotype to phenotype assays should result in improved treatment and will inform on drug stockpiling strategy in case of pandemic.
Competitiondate
202407
Approvedterm2
1 yr 0 mth
Pinamesdelim
Boivin, Guy; Côté, Marceline; Finzi, Andrés
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $150,000~ $0~
Université Laval - $150,000 Grant (2024-25) | Canada Spends